Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan plus chemotherapy vs chemotherapy in relapsed/refractory AML (China bridging)
CTR20202416Phase 3Terminated
- Sponsor
- Kwan Ko Mei Po
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of uproleselan in acute myeloid leukemia (AML), sponsored by Kwan Ko Mei Po. Started Dec 2020; status: terminated.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20202416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202416.